Skip to main content
SpringerLink
Log in

Nefiracetam

DM 9384, DZL 221, Translon®

  • Section 2: Dementia Syndrome in Japan
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fujimaki Y, Sudo K, Hakusui H, et al. Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers. J Pharm Pharmacol 1992 Sep; 44: 750–4

    Article  PubMed  CAS  Google Scholar 

  2. Fujimaki Y, Sudo K, Hakusui H. Pharmacokinetics of nefiracetam and 3 metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring. Xenobiotica 1993 Jan; 23: 61–70

    Article  PubMed  CAS  Google Scholar 

  3. Kobayashi T, Ikeda M, Orishige T, et al. Investigation of DM-9384 (nefiracetam) in a long-term treatment of patients with after-effect of cerebrovascular disorders. Yakuri to Chiryo 1994 Aug; 22: 3645–59

    Google Scholar 

  4. Hasegawa T, Shigeno K, Hirata Y, et al. Clinical evaluation of DM-9384 (nefiracetam) in a long-term treatment of patients with sequela of cerebrovascular disorders. Rinsho Iyaku 1994; 10 No. 9: 2087–106

    Google Scholar 

  5. Ohtomo E, Kogure K, Hirai S, et al. Clinical utility of DM-9384 (nefiracetam) in patients with aftereffect following cerebrovascular disorders: a comparative double-blind study with idebenone. Rinsho Iyaku 1994; 10 No. 8: 1871–918

    Google Scholar 

  6. Ohtomo E, Kogure K, Hirai S, et al. Clinical utility of DM-9384 (Nefiracetam) in the treatment of cerebrovascular disorders: dose finding study by double-blind method. Rinsho Iyaku 1994; 10 No. 7: 1507–47

    Google Scholar 

  7. Goa KL, Benfield P. Nefiracetam. CNS Drugs 1996 Oct; 6: 331–7

    Article  CAS  Google Scholar 

  8. Watabe S, Yamaguchi H, Ashida S. Effect of DM-9384, a new cognition-enhancing agent, on GABA and cholinergic systems in rat cortex. Jap J Pharmacol 1990; 52 Suppl. 1: 294

    Google Scholar 

  9. Nabeshima T, Noda Y, Tohyama K, et al. Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Eur J Pharmacol 1990 Mar 20; 178: 143–9

    Article  PubMed  CAS  Google Scholar 

  10. Kawajira S, Taniguchi K, Sakurai T, et al. Effect of DM-9384 on extracellular acetylcholine in the rat frontal cortex measured with microdialysis. Eur J Pharmacol 1990 Jul; 183: 928

    Article  Google Scholar 

  11. Murai S, Saito H, Abe E, et al. Effect of acute and subchronic administration of DM-9384 and some cognition enhancers on the monoaminergic systems in certain regions of the mouse brain. Jap J Pharmacol 1991; 55 Suppl. 1: 204

    Google Scholar 

  12. Abe E, Murai S, Saito H, et al. Effects of nefiracetam, a novel pyrrolidone derivative, on brain monoamine metabolisms in mice. J Neural Transm Gen Sect 1992; 90 No. 2: 125–36

    Article  PubMed  CAS  Google Scholar 

  13. Murashima YL, Shinozaki T, Watabe S, et al. Regulation of cAMPby nefiracetam (DM-9384), a nootropic agent, through G-proteins in NG108-15 cells. Fourth IBROWorld Congress of Neuroscience; 1995 Jul 9; 138

    Google Scholar 

  14. Yoshii M, Watabe S, Murashima YL, et al. Enhancement of cAMP and inhibition of calcium signaling pathways by the nootropic agent nefiracetam (DM-9384) in NG108-15 cells. Fourth IBROWorld Congress of Neuroscience; 1995 Jul 9; 125

    Google Scholar 

  15. Sakurai T, Hatanaka S, Tanaka S, et al. Protective effect of DM-9384, a novel pyrrolidine derivative, against experimental cerebral anoxia. Jap J Pharmacol 1990 Sep; 54: 33–43

    Article  PubMed  CAS  Google Scholar 

  16. Nabeshima T, Tohyama K, Murase K, et al. Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases inGABAAandMuscarinic receptors induced by cycloheximide. J Pharmacol Exp Ther 1991 Apr; 257: 271–5

    PubMed  CAS  Google Scholar 

  17. Shiotani T, Tohyama K, Murase K, et al. Effects of nefiracetam, DM-9384 on amnesia and decrease in cholineacetyltransferase activity induced by cycloheximide. J Neural Transm Gen Sect 1992; 90 (2): 103–11

    Article  PubMed  CAS  Google Scholar 

  18. Hiramatsu M, Koide T, Ishihara S-i, et al. Involvement of the cholinergic system in the effects of nefiracetam (DM-9384) on carbon monoxide (CO)-induced acute and delayed amnesia. Eur J Pharmacol 1992 Jun 5; 216: 279–85

    Article  PubMed  CAS  Google Scholar 

  19. Tanaka S, Shirasaki Y, Yamada F, et al. Impairment effect of DM-9384, a new cognition enhancer, on learning deficits in cerebral embolized rats. Jap J Pharmacol 1990; 52 Suppl. 1: 74

    Google Scholar 

  20. Woodruff-Pak D. Nefiracetam. CNS Drugs 1996 Oct; 6: 338

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nefiracetam. Drugs R&D 2, 137–141 (1999). https://doi.org/10.2165/00126839-199902020-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902020-00015

Keywords

Search

Navigation